151 related articles for article (PubMed ID: 36111242)
1. Immunotherapeutic Value of Transcription Factor 19 (TCF19) Associated with Renal Clear Cell Carcinoma: A Comprehensive Analysis of 33 Human Cancer Cases.
Cheng X; Hou J; Wen X; Dong R; Lu Z; Jiang Y; Wu G; Yuan Y
J Oncol; 2022; 2022():1488165. PubMed ID: 36111242
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase.
Shi Y; Ju M; Zhang Y; Liang L; Sun X; Di X
Medicine (Baltimore); 2024 Mar; 103(12):e37362. PubMed ID: 38518034
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.
Wen X; Hou J; Chu Y; Liao G; Wu G; Fang S; Xiao S; Qiu L; Xiong L
Am J Cancer Res; 2024; 14(3):959-978. PubMed ID: 38590423
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis.
Zhao Z; Yang Y; Liu Z; Chen H; Guan X; Jiang Z; Yang M; Liu H; Chen T; Gao Y; Zou S; Wang X
Front Mol Biosci; 2022; 9():951636. PubMed ID: 36188226
[No Abstract] [Full Text] [Related]
6. A comprehensive pancancer analysis reveals the potential value of RAR-related orphan receptor C (RORC) for cancer immunotherapy.
He S; Yu J; Sun W; Sun Y; Tang M; Meng B; Liu Y; Li J
Front Genet; 2022; 13():969476. PubMed ID: 36186454
[No Abstract] [Full Text] [Related]
7. TCF19 Impacts a Network of Inflammatory and DNA Damage Response Genes in the Pancreatic β-Cell.
Yang GH; Fontaine DA; Lodh S; Blumer JT; Roopra A; Davis DB
Metabolites; 2021 Aug; 11(8):. PubMed ID: 34436454
[TBL] [Abstract][Full Text] [Related]
8. Multidimensional data analysis revealed thyroiditis-associated TCF19 SNP rs2073724 as a highly ranked protective variant in thyroid cancer.
Ruan X; Liu Y; Wu S; Fu G; Tao M; Huang Y; Li D; Wei S; Gao M; Guo S; Ning J; Zheng X
Aging (Albany NY); 2024 Apr; 16(7):6488-6509. PubMed ID: 38579171
[TBL] [Abstract][Full Text] [Related]
9. TCF19 and p53 regulate transcription of TIGAR and SCO2 in HCC for mitochondrial energy metabolism and stress adaptation.
Mondal P; Gadad SS; Adhikari S; Ramos EI; Sen S; Prasad P; Das C
FASEB J; 2021 Sep; 35(9):e21814. PubMed ID: 34369624
[TBL] [Abstract][Full Text] [Related]
10. TCF19 enhances cell proliferation in hepatocellular carcinoma by activating the ATK/FOXO1 signaling pathway.
Zeng CX; Fu SB; Feng WS; Zhao JY; Li FX; Gao P
Neoplasma; 2019 Jan; 66(1):46-53. PubMed ID: 30509085
[TBL] [Abstract][Full Text] [Related]
11. TCF19 contributes to cell proliferation of non-small cell lung cancer by inhibiting FOXO1.
Zhou ZH; Chen G; Deng C; Tang JM; Xie L; Zhou HY; Ye X; Zhang DK; Shi RQ; Tian D; Qiao GB; Ben XS
Cell Biol Int; 2019 Dec; 43(12):1416-1424. PubMed ID: 31141247
[TBL] [Abstract][Full Text] [Related]
12. S100A8 as a Promising Biomarker and Oncogenic Immune Protein in the Tumor Microenvironment: An Integrative Pancancer Analysis.
Wu Z; Jiang D; Huang X; Cai M; Yuan K; Huang P
J Oncol; 2022; 2022():6947652. PubMed ID: 35646116
[TBL] [Abstract][Full Text] [Related]
13. In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis.
Wu Z; Jiang Y; Huang X; Cai M; Yuan K; Huang P; Wang Z
Evid Based Complement Alternat Med; 2022; 2022():7730433. PubMed ID: 35463077
[TBL] [Abstract][Full Text] [Related]
14. Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8
Ma X; Wang Q; Sun C; Agarwal I; Wu H; Chen J; Zhao C; Qi G; Teng Q; Yuan C; Yan S; Peng J; Li R; Song K; Zhang Q; Kong B
Cell Rep; 2023 Aug; 42(8):112944. PubMed ID: 37566545
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
17. Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types.
Liu T; Zhang J; Lin C; Liu G; Xie G; Dai Z; Yu P; Wang J; Guo L
Front Cell Dev Biol; 2022; 10():839136. PubMed ID: 35372330
[No Abstract] [Full Text] [Related]
18. Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis.
Wang S; Wei X; Ji C; Wang Y; Zhang X; Cong R; Song N
Front Oncol; 2022; 12():781932. PubMed ID: 35356208
[TBL] [Abstract][Full Text] [Related]
19. Tcf19 is a novel islet factor necessary for proliferation and survival in the INS-1 β-cell line.
Krautkramer KA; Linnemann AK; Fontaine DA; Whillock AL; Harris TW; Schleis GJ; Truchan NA; Marty-Santos L; Lavine JA; Cleaver O; Kimple ME; Davis DB
Am J Physiol Endocrinol Metab; 2013 Sep; 305(5):E600-10. PubMed ID: 23860123
[TBL] [Abstract][Full Text] [Related]
20. TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark.
Mondal P; Sen S; Klein BJ; Tiwary N; Gadad SS; Kutateladze TG; Roy S; Das C
Biochemistry; 2020 Feb; 59(4):389-399. PubMed ID: 31746185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
